Personalized Drug Screening for Functional Tumor Profiling

Using the patient's tumor cells, personalized drug screening allows the identification of the right drug to the right cancer patient.

Victoria El-Khoury (Author), Tatiana Michel (Author), Hichul Kim (Author), Yong-Jun Kwon (Author)

9781009016933, Cambridge University Press

Paperback / softback, published 7 July 2022

75 pages
22.8 x 15.1 x 0.2 cm, 0.06 kg

Despite considerable advances in our understanding of the biology that underlies tumor development and progression of cancer and the rapidly evolving field of personalized medicine, cancer is still one of the deadliest diseases. Many cancer patients have benefited from the survival improvements observed with targeted therapies but only a small subset of patients receiving targeted drugs experience an objective response. Because cancer is a complex and heterogeneous disease, the search for effective cancer treatments will need to address not only patient-specific molecular defects but also aspects of the tumor microenvironment. The functional tumor profiling directly measures the cellular phenotype, in particular tumor growth, in response to drugs using patient-derived tumor models and might be the next step toward precision oncology. In this Element, the authors discuss the personalized drug screening as a novel patient stratification strategy for the determination of individualized treatment choices in oncology.

1. Rationale for functional profiling in oncology
2. Tumor models in drug screening
3. Cell-based screening platforms for personalized medicine
4. Drug repurposing in personalized oncomedicine
5. Clinical applications of drug screening in oncology
6. Conclusions and perspectives
References.

Subject Areas: Oncology [MJCL], Medicine: general issues [MB]